Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial

Shimura, MasahikoMasahikoShimuraKitano, ShigehikoShigehikoKitanoOgata, NahokoNahokoOgataMitamura, YoshinoriYoshinoriMitamuraOh, HideyasuHideyasuOhOchi, HarukaHarukaOchiOhsawa, ShinoShinoOhsawaHirakata, AkitoAkitoHirakataCHANG-HAO YANG et al.2024-01-182024-01-182023-0500215155https://scholars.lib.ntu.edu.tw/handle/123456789/638609To evaluate efficacy, durability, and safety of faricimab in Japanese patients with diabetic macular edema (DME).enAngiopoietin-2; Anti-VEGF therapy; Diabetic macular edema; Faricimab; Vascular stabilityEfficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trialjournal article10.1007/s10384-023-00979-8368974132-s2.0-85159762158https://api.elsevier.com/content/abstract/scopus_id/85159762158